Literature DB >> 20648092

Practical approach to the use of corticosteroids in patients with uveitis.

Emmett T Cunningham1, Jon D Wender.   

Abstract

Corticosteroids constitute the first line of therapy for patients with noninfectious ocular inflammatory disease. We review factors contributing to the clinical effectiveness of various corticosteroid preparations in patients with uveitis and discuss practical aspects regarding treatment indications, when to administer various agents, and how best to dose and monitor for both treatment and adverse effects. Topically administered corticosteroids are typically indicated for the treatment of anterior uveitis, whereas periocular or intravitreal agents are employed most often in the management of intermediate or posterior intraocular inflammation. Patients with vision-threatening uveitis, bilateral inflammation, or uveitis occurring in the setting of systemic involvement may require oral or intravenous administration of corticosteroids. Noncorticosteroid immunosuppressive agents play an important role in limiting the toxic effects of long-term corticosteroid use.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20648092     DOI: 10.3129/i10-081

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  13 in total

1.  [Monitoring treatment with biologics in non-infectious uveitis].

Authors:  T Barisani-Asenbauer
Journal:  Ophthalmologe       Date:  2011-01       Impact factor: 1.059

2.  Do systemic steroids increase the risk of ocular complication in uveitis patients? Focus on a Italian referral center.

Authors:  Chiara Posarelli; Rosaria Talarico; Giovanna Vella; Andrea Passani; Marta Mosca; Michele Figus
Journal:  Clin Rheumatol       Date:  2019-06-06       Impact factor: 2.980

3.  [Intermediate uveitis: guidelines of the German Ophthalmological Society and the Professional Association of German Ophthalmologists].

Authors:  F Mackensen; L Baydoun; J Garweg; A Heiligenhaus; T Hudde
Journal:  Ophthalmologe       Date:  2014-11       Impact factor: 1.059

Review 4.  [Guidelines nr. 24a intermediate uveitis].

Authors: 
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

5.  [Atypical retinal vasculitis].

Authors:  A William; C Rössler; C Binder
Journal:  Ophthalmologe       Date:  2018-08       Impact factor: 1.059

6.  [Therapy of intermediate uveitis].

Authors:  D Doycheva; C Deuter; M Zierhut
Journal:  Ophthalmologe       Date:  2014-12       Impact factor: 1.059

7.  Steroid-eluting contact lenses for corneal and intraocular inflammation.

Authors:  Lokendrakumar C Bengani; Hidenaga Kobashi; Amy E Ross; Hualei Zhai; Borja Salvador-Culla; Rekha Tulsan; Paraskevi E Kolovou; Sharad K Mittal; Sunil K Chauhan; Daniel S Kohane; Joseph B Ciolino
Journal:  Acta Biomater       Date:  2020-08-16       Impact factor: 8.947

Review 8.  Medical management of uveitis - current trends.

Authors:  Kalpana Babu; Padmamalini Mahendradas
Journal:  Indian J Ophthalmol       Date:  2013-06       Impact factor: 1.848

9.  Kinetics of hydrocortisone sodium phosphate penetration into the human aqueous humor after topical application.

Authors:  Carlo Cagini; Alessio Muzi; Greta Castellucci; Giulia Ragna; Marco Lupidi; Husam B R Alabed; Roberto Maria Pellegrino
Journal:  Int J Clin Pract       Date:  2021-10-26       Impact factor: 3.149

10.  Superoxide Dismutase 1 Nanozyme for Treatment of Eye Inflammation.

Authors:  Olga A Kost; Olga V Beznos; Nina G Davydova; Devika S Manickam; Irina I Nikolskaya; Anna E Guller; Petr V Binevski; Natalia B Chesnokova; Anatoly B Shekhter; Natalia L Klyachko; Alexander V Kabanov
Journal:  Oxid Med Cell Longev       Date:  2015-12-01       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.